EWTX logo

EWTX
Edgewise Therapeutics Inc

603
Mkt Cap
$3.8B
Volume
543,161.00
52W High
$39.96
52W Low
$12.15
PE Ratio
-21.27
EWTX Fundamentals
Price
$34.34
Prev Close
$35.32
Open
$35.70
50D MA
$31.60
Beta
1.39
Avg. Volume
990,254.29
EPS (Annual)
-$1.63
P/B
7.70
Rev/Employee
$0.00
$2,028.11
Loading...
Loading...
News
all
press releases
Joanne Donovan Sells 50,000 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock
Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 50,000 shares of the firm's stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the transaction, the...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells $163,646.70 in Stock
Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 5,230 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $31.29, for a total value of $163,646.70. Following the sale, the chief marketing officer owned...
MarketBeat·6d ago
News Placeholder
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?
The company said Aficamten for patients with symptomatic non-obstructive hypertrophic cardiomyopathy met both primary endpoints.
Stocktwits·6d ago
News Placeholder
Edgewise Therapeutics (NASDAQ:EWTX) Sets New 52-Week High - Should You Buy?
Edgewise Therapeutics (NASDAQ:EWTX) Hits New 1-Year High - Time to Buy...
MarketBeat·6d ago
News Placeholder
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER...
PR Newswire·7d ago
News Placeholder
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Analysts
Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, MarketBeat.com...
MarketBeat·10d ago
News Placeholder
Edgewise Therapeutics (EWTX) to Release Earnings on Thursday
Edgewise Therapeutics (NASDAQ:EWTX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat·11d ago
News Placeholder
Moody Aldrich Partners LLC Has $1.07 Million Holdings in Edgewise Therapeutics, Inc. $EWTX
Moody Aldrich Partners LLC cut its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 48.0% in the fourth quarter, according to the company in its most recent filing with the...
MarketBeat·11d ago
News Placeholder
Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Here's What Happened
Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Should You Buy...
MarketBeat·13d ago
News Placeholder
Edgewise Therapeutics, Inc. $EWTX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 104.8% during the 4th quarter, according to its most recent 13F...
MarketBeat·13d ago
<
1
2
...
>

Latest EWTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.